Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Report Guidance 6 Clinical Trials by Region 7 Clinical Trials and Average Enrollment by Country 8 Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10 Top Five Countries Contributing to Clinical Trials in Europe 11 Top Countries Contributing to Clinical Trials in North America 12 Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13 Top Five Countries Contributing to Clinical Trials in Central and South America 14 Clinical Trials by G7 Countries: Proportion of Ovarian Cancer to Oncology Clinical Trials 15 Clinical Trials by Phase in G7 Countries 16 Clinical Trials in G7 Countries by Trial Status 17 Clinical Trials by E7 Countries: Proportion of Ovarian Cancer to Oncology Clinical Trials 18 Clinical Trials by Phase in E7 Countries 19 Clinical Trials in E7 Countries by Trial Status 20 Clinical Trials by Phase 21 In Progress Trials by Phase 22 Clinical Trials by Trial Status 23 Clinical Trials by End Point Status 24 Subjects Recruited Over a Period of Time 25 Clinical Trials by Sponsor Type 26 Prominent Sponsors 27 Top Companies Participating in Ovarian Cancer Therapeutics Clinical Trials 28 Prominent Drugs 29 Latest Clinical Trials News on Ovarian Cancer 30 May 02, 2016: Novogen Provides Update On Development Of Cantrixil 30 May 02, 2016: Celsion Announces Positive Data from the First Cohort of Patients in the OVATION Study 30 Apr 29, 2016: SELLAS Life Sciences Group Announces Initiation of Galinpepimut-S (WT1 Cancer Vaccine) Phase 1 Clinical Trial in Combination with PD-1 Checkpoint Inhibitor for Patients with Ovarian Cancer 31 Apr 25, 2016: Cerulean Announces Oral Presentation of CRLX101 Clinical Data at Gynecologic Oncology 2016 Conference 32 Apr 21, 2016: Merrimack Unveils its Latest Antibody Directed Nanotherapeutic, MM-310, at the 2016 AACR Annual Meeting 33 Apr 21, 2016: OncoMed Announces Clinical Data for ipafricept to be Presented at the 2016 ASCO Annual Meeting 34 Apr 21, 2016: TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute 34 Apr 19, 2016: Celsion Presents Compelling Data at AACR 2016 Demonstrating Synergistic Anti-Cancer Effect of GEN-1 IL-12 Immunotherapy Plus Avastin and Doxil 35 Apr 19, 2016: Cerulean Announces Presentation at 2016 American Association for Cancer Research Annual Meeting of Stage 1 Data from Phase 2 Trial in Platinum-Resistant Ovarian Cancer 35 Apr 19, 2016: MacroGenics Presents Data from ROR1 x CD3 DART Preclinical Program at AACR Annual Meeting 2016 36 Apr 19, 2016: New class of small molecule drug, SI-2, has potential for improving cancer treatment 37 Apr 18, 2016: DelMar's VAL-083 Demonstrates Promise in the Treatment of Non-Small Cell Lung Cancer and Ovarian Cancer 37 Apr 18, 2016: Morphotek Announces Publication of Phase 3 Results From MORAb-003-004 Trial in Platinum-Sensitive Ovarian Cancer Patients 38 Apr 17, 2016: Precision Biologics, a NantWorks Company, to Present Combination Immunotherapy of a Novel Neo-Epitope Antibody Targeting Ovarian and Uterine Cancer at the AACR Annual Meeting 2016 39 Apr 14, 2016: Asana BioSciences, to Provide First Presentation of Pre-Clinical Data on its Novel ERK 1/2 Inhibitor Program at the American Association for Cancer Research Annual Meeting 39 Apr 12, 2016: Celsion Announces Upcoming Presentation at AACR 2016 Highlighting Potential of GEN-1 IL-12 Immunotherapy in Ovarian Cancer 40 Apr 07, 2016: TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine 40 Apr 01, 2016: Array BioPharma Announces Decision To Discontinue MILO Study In Ovarian Cancer 41 Apr 01, 2016: SELLAS Life Sciences to Present Phase 2 Clinical Results for WT1 Cancer Vaccine at the 2016 ASCO Annual Meeting and the 13th International Conference of the International Mesothelioma Interest Group (iMig) 41 Mar 31, 2016: Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer 42 Mar 22, 2016: CytRx to Present New Data Using Its Proprietary LADR Technology at the 2016 American Association for Cancer Research Annual Meeting 43 Mar 21, 2016: Oncolytics Biotech Reports Data from Randomized Phase 2 Study of REOLYSIN in Ovarian Cancer 43 Mar 16, 2016: Celsion Announces Presentation of Preclinical Data for GEN-1 IL-12 Immunotherapy in Combination with Avastin and Doxil at the AACR Annual Meeting 2016 44 Mar 16, 2016: Verastem to Present Data Supporting FAK/PYK2 Inhibition at the 2016 American Academy of Cancer Research Annual Meeting 46 Mar 16, 2016: Cerulean Announces Data Presentation at the 2016 American Association for Cancer Research Annual Meeting 46 Mar 16, 2016: Verastem to present data supporting FAK inhibition at the 2016 American Academy of cancer research annual meeting 47 Mar 10, 2016: PsiOxus Therapeutics Initiates Combination of Paclitaxel with Oncolytic Virus Enadenotucirev in Ovarian Cancer Study 48 Mar 08, 2016: Innovative Approach to Ovarian Cancer Treatment Unveiled by Biomedical Scientists at the Lankenau Institute for Medical Research 49 Mar 04, 2016: Karyopharm’s Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology 49 Mar 02, 2016: Propanc Confirms PRP Response to Broad Range of Cancer Indications; Sets Date for Scientific Advice Meeting with UK Regulators 50 Feb 16, 2016: Critical Outcome Treats First Patient in Phase 1 Study of COTI-2 in Gynecologic Cancers 51 Feb 12, 2016: Celsion Highlights Recent Pipeline Developments for its GEN-1 Immunotherapy Program and Provides Business Update 51 Feb 10, 2016: Cellceutix Meets With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian Cancer 52 Clinical Trial Profile Snapshots 54 Appendix 1722 Abbreviations 1722 Definitions 1722 Research Methodology 1723 Secondary Research 1723 About GlobalData 1724 Contact Us 1724 Disclaimer 1724 Source 1725

List of Tables Ovarian Cancer Therapeutics, Global, Clinical Trials by Region, 2016* 7 Ovarian Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8 Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9 Ovarian Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10 Ovarian Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11 Ovarian Cancer Therapeutics Clinical Trials, North America, Top Countries, 2016* 12 Ovarian Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 13 Ovarian Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 14 Proportion of Ovarian Cancer to Oncology Clinical Trials, G7 Countries (%), 2016* 15 Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16 Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17 Proportion of Ovarian Cancer to Oncology Clinical Trials, E7 Countries (%), 2016* 18 Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19 Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20 Ovarian Cancer Therapeutics, Global, Clinical Trials by Phase, 2016* 21 Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22 Ovarian Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23 Ovarian Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24 Ovarian Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25 Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26 Ovarian Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27 Ovarian Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28 Ovarian Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29 List of Figures Ovarian Cancer Therapeutics, Global, Clinical Trials by Region (%), 2016* 7 Ovarian Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8 Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9 Ovarian Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10 Ovarian Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11 Ovarian Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12 Ovarian Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 13 Ovarian Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14 Proportion of Ovarian Cancer to Oncology Clinical Trials, G7 Countries (%), 2016* 15 Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16 Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17 Proportion of Ovarian Cancer to Oncology Clinical Trials, E7 Countries (%), 2016* 18 Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19 Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20 Ovarian Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21 Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22 Ovarian Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23 Ovarian Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24 Ovarian Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25 Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26 Ovarian Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27 Ovarian Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28 Ovarian Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29 GlobalData Methodology 1723

F. Hoffmann-La Roche Ltd. AstraZeneca Plc Sanofi GlaxoSmithKline Plc Merck & Co., Inc. AbbVie Inc. Eli Lilly and Company Novartis AG Pfizer Inc. Johnson & Johnson